Myriad Genetics (MYGN) Research & Development (2009 - 2026)

Myriad Genetics (MYGN) has reported Research & Development for 18 consecutive years, with $27.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 1.45% year-over-year to $27.1 million; the TTM figure through Mar 2026 stood at $152.7 million (up 407.31% YoY), while the FY2025 annual figure was $106.8 million, down 5.82% from the prior year.
• Research & Development improved to $27.1 million in Q1 2026 per MYGN's latest filing, from $25.5 million in the prior quarter.
• Across five years, Research & Development topped out at $204.8 million in Q4 2022 and bottomed at -$98.7 million in Q4 2024.
• Historically, Research & Development has averaged $35.7 million across 5 years, with a median of $25.5 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development jumped 899.02% — and 2024, when it slumped 570.0%.
• Myriad Genetics' Research & Development stood at $204.8 million in 2022, then plunged by 89.75% to $21.0 million in 2023, then plunged by 570.0% to -$98.7 million in 2024, then jumped by 125.84% to $25.5 million in 2025, then gained by 6.27% to $27.1 million in 2026.
• Business Quant data shows MYGN's Research & Development at $27.1 million in Q1 2026, $25.5 million in Q4 2025, and $28.2 million in Q3 2025.